

A kit for predicting the therapeutic response to antipsychotic drugs

IDIVAL, in collaboration with CSIC, UC and CIBER, has developed a kit for predicting the therapeutic response to antipsychotic drugs.

Antipsychotic drugs

Antipsychotic drugs, also termed as tranquilizers or neuroleptics, are the cornerstone to treat psychotic disorders. An adequate treatment at initial stages of the psychotic disorder is crucial to improve the prognosis of this clinical condition.

Despite being one of the largest types of prescribed drugs and having large inter-individual differences in efficacy, no methodology to predict the treatment response in patients with psychotic disorders is currently available. There are no molecular tests available that allow predicting the clinical response to antipsychotic treatments.

Here we present a method for predicting, before treatment, the individual clinical response to antipsychotic medication in subjects suffering from psychosis disorders. This method is based on a gene expression profile and allows the selection of patients for further or alternative antipsychotic therapies.

Competitive advantages

The main competitive advantages of the predictor kit are:

- It is useful to predict the therapeutic response to antipsychotics in drug – naïve patients.
- It allows the selection of patients for further or alternative antipsychotic therapies.
- It is useful for the identification, in early stages before the treatment, of those patients that will or will not respond to the antipsychotic drugs, which allow designing specific individual therapeutic strategies for each patient.

Supporting Data


The method has been tested in biological samples obtained from antipsychotic naïve patients.

Market insight

Antipsychotic medications are among the most common and costly prescribed drugs with significant increases in overall prescription in recent years. Only in relation to schizophrenia, GlobalData estimates that during the year 2015 product sales were approximately \$6.4 billion over 7MM. Global drug sales for schizophrenia are expected to reach \$ 7.3 billion by 2015, with a Growth Rate (CAGR) of 1.4%.

Patent Protection

A patent application covering this technology has been filed through Spanish Patent Application P201730464. IDIVAL would like to talk to companies interested in commercializing this device or in a research cooperation agreement to develop it.



Principal researchers:

Benedicto Crespo Facorro

Hospital Universitario Marqués de Valdecilla (HUMV) - Universidad de Cantabria (UC)

Jesús Vicente Sainz Maza

Consejo Superior de Investigaciones Científicas (CSIC)

For further information please contact:

Patricia Zorrilla de la Fuente

Technology Transfer Office- IDIVAL

otri@idival.org

+34.942.31.55.15 Ext 073144

www.idival.org Santander, Spain